Novel ganaplacide/lumefantrine-SDF combination in adults and children with malaria moves to Phase III study
Novartis and Medicines for Malaria Venture (MMV) have announced the decision to progress ganaplacide/lumefantrine-solid dispersion formulation (SDF) into Phase III development for the treatment of patients with acute uncomplicated malaria caused by Plasmodium falciparum and P. vivax. Ganaplacide (previously known as KAF156) is a novel antimalarial compound with a new mechanism of action, and is the partner drug with a new formulation of lumefantrine optimised for once-daily dosing. The Phase III study will be conducted by the West African Network for Clinical Trials of Antimalarial Drugs (WANECAM 2) consortium. EDCTP is investing EUR 10 million with an additional EUR 1 million from the German Federal Ministry for Education and Research (BMBF) in support of developing this promising novel antimalarial treatment.